Genetic Technologies Interview to Air on Bloomberg International on the RedChip Money Report
18 May 2019 - 3:30AM
Molecular diagnostics company Genetic Technologies Limited (ASX:
GTG; NASDAQ: GENE) is pleased to announce an interview with
its Chairman and CEO, Paul Kasian, will air on The RedChip Money
Report television program. The interview will air Sunday, May 19,
on Bloomberg International, available in 149 million homes across
Europe, the Middle East, and Africa. Check local listings for times
in your area.
In the exclusive interview, Kasian discusses Genetic
Technologies’ recent developments, including the launch of its risk
assessment tests for non-hereditary and hereditary breast cancer
and colorectal cancer, as well as insight into the company’s robust
development pipeline of innovative tests.
To view the interview segment, please visit:
https://www.redchip.com/media/2114/
“The RedChip Money Report" delivers insightful commentary on
small-cap investing, interviews with Wall Street analysts,
financial book reviews, as well as featured interviews with
executives of public companies.
About Genetic Technologies Limited
Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE) is a
diversified molecular diagnostics company. GTG offers cancer
predictive testing and assessment tools to help physicians
proactively manage patient health. The Company’s lead product,
BREVAGenplus®, is a clinically validated risk assessment test for
non-hereditary breast cancer and is first in its class. For more
information, please visit www.brevagenplus.com and
www.phenogensciences.com.
Genetic Technologies is developing a pipeline of risk assessment
products including a novel colorectal cancer (CRC) test. For more
information, please visit www.gtgcorporate.com
Safe Harbor Statement
Any statements in this press release that relate to the
Company's expectations are forward-looking statements, within the
meaning of the Private Securities Litigation Reform Act. The
Private Securities Litigation Reform Act of 1995 (PSLRA)
implemented several significant substantive changes affecting
certain cases brought under the federal securities laws, including
changes related to pleading, discovery, liability, class
representation and awards fees. Since this information may involve
risks and uncertainties and are subject to change at any time, the
Company's actual results may differ materially from expected
results. Additional risks associated with Genetic Technologies'
business can be found in its periodic filings with the SEC.
Investor Contact:
Victor RobertsRedChip Companies
407-644-4256victor@redchip.com
Genetic Technologies (NASDAQ:GENE)
Historical Stock Chart
From Apr 2024 to May 2024
Genetic Technologies (NASDAQ:GENE)
Historical Stock Chart
From May 2023 to May 2024